Full text is available at the source.
Abstract
Lipid-based nanoparticles (LNPs) may enhance the efficacy, safety, and patient adherence of antidiabetic therapies.
- Solid Lipid Nanoparticles (SLNs) provide excellent stability and controlled release of drugs.
- Nanostructured Lipid Carriers (NLCs) improve drug loading and flexibility compared to other systems.
- Liposomes can encapsulate both hydrophilic and lipophilic drugs, offering versatile applications.
- Nanoemulsions are particularly effective for enhancing the rapid absorption of poorly soluble agents.
- These lipid-based systems may outperform conventional formulations in therapeutic outcomes and reducing side effects.
- Challenges exist in large-scale manufacturing and regulatory processes that may impact translational research.
Simplified